New Iron Treatment Funded For People Who Have Experienced Serious Reactions

From 1 March 2026 Pharmac will fund ferric derisomaltose (Monofer) in hospitals for people who have experienced serious reactions after other iron infusions.

Pharmac consulted on a proposal to fund this medicine in January, following the discontinuation of iron as sucrose (Venofer) which is used by people who have experienced hypophosphataemia after other iron infusions.

Hypophosphataemia is a rare but serious side effect of some iron infusions. It means having low levels of phosphate in the blood, a mineral that is important for healthy bones, muscles, and energy.

“The consultation feedback Pharmac received was supportive, but strongly suggested widening the funding criteria further,” says Senior Therapeutic Group Manager/Team Leader, Josh Wiles.

“Clinicians told us that a small number of patients who experience adverse reactions to other funded iron transfusions would also benefit from this treatment.”

After considering this response Pharmac has decided to fund ferric derisomaltose (Monofer) in hospitals for all people who have experienced a serious reaction after other funded iron transfusions.

“Supplies of Venofer are expected to run out by March 2026. Funding ferric derisomaltose means people with hypophosphataemia will continue to have access to a safe iron infusion option,” says Wiles.

“Expanding the criteria means anyone who hasn’t been able to tolerate an iron infusion before can now get this treatment. This should reduce the number of infusions they need and cut down their time in hospital.”

Approximately 100 people are expected to benefit from this treatment each year.

Submissions on the proposal also called for Monofer to be funded for people with Hereditary Haemorrhagic Telangiectasia (HHT) who have an increased risk of experiencing hypophosphataemia after receiving some iron transfusions.

Pharmac is currently assessing an application to fund Monofer for people with HHT. Assessment of this application will include consideration of the feedback received in recent consultation.

© Scoop Media